GAO Investigation Reveals Gaps in FDA Drug Reviews for Seniors |
Rep. Henry A. Waxman and Sen. Edward M. Kennedy today released a new GAO report on FDA’s inclusion of seniors in clinical drug trials for prescription drugs. The report finds that in several key areas, FDA rules for drug approval fail to guarantee the safety and effectiveness of drugs for seniors. To conduct the study, GAO reviewed 36 New Drug Applications (NDA) filed with FDA from January 1, 2001, through June 30, 2004. Findings of the report include:
Documents and Links |
Committee On Oversight and Government Reform
U.S. House of Representatives | 2157 Rayburn House Office Building | Washington, D.C. 20515 | (202) 225-5051